What Is BPC‑157? BPC‑157 (Body Protection Compound‑157) is a stable synthetic pentadecapeptide fragment originating from a naturally occurring protein in human gastric juice. It has attracted significant research interest for its broad cytoprotective and regenerative potential, particularly in preclinical models of tissue injury and inflammation. Mechanism of Action BPC‑157 interacts with multiple molecular pathways, including modulation of angiogenesis via vascular endothelial growth factor (VEGF) signaling, nitric oxide synthesis, and upregulation of growth factor cascades. It enhances fibroblast migration, collagen deposition, and microvascular repair, contributing to accelerated wound healing. Additionally, BPC‑157 demonstrates protective effects against gastrointestinal mucosal damage, neurovascular injury, and musculoskeletal degeneration. Its pleiotropic activity is thought to arise from stabilization of endothelial junctions and modulation of inflammatory mediators. Research & Clinical Data Although not FDA‑ or EMA‑approved, BPC‑157 has been extensively studied in animal models. Evidence suggests efficacy in tendon‑to‑bone healing, gastric ulcer protection, spinal cord injury recovery, and counteraction of NSAID‑induced toxicity. Clinical trials remain limited, with ongoing investigations into its potential therapeutic role in human musculoskeletal and gastrointestinal disorders. Purity & Quality Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not approved for therapeutic use. Classification & Handling Class: Synthetic pentadecapeptide | Source: Human gastric juice protein fragment | Administration: Investigational, parenteral routes in studies | Storage: 2–8°C refrigerated, protect from light | Regulatory: Not FDA/EMA approved